Susan D. Richman

6.4k citations

76 papers · 3.2k indexed · 2 hit papers · h-index 21

Oncology top 1%
- Colorectal Cancer Treatments and Studies 59
- Cancer Treatment and Pharmacology 10
- Colorectal Cancer Screening and Detection 9
Pathology and Forensic Medicine top 0.5%
- Genetic factors in colorectal cancer 26
Cancer Research top 2%
- Cancer Genomics and Diagnostics 24
Hepatology top 2%
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 18
- Gastric Cancer Management and Outcomes 10
Surgery
- Colorectal and Anal Carcinomas 9

Co-authors: Philip Quirke Michel Seymour Philip Chambers Catherine Daly Faye Elliott Jennifer H. Barrett Angela Meade Tim Maughan
Cited by: Oncology Pathology and Forensic Medicine Cancer Research
Journals: Journal of Clinical Oncology (20 papers)Annals of Oncology (7 papers)Journal of Clinical Pathology (4 papers)
Partner nations: United Kingdom United States Netherlands

In The Last Decade

Susan D. Richman

72 papers receiving 3.2k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Susan D. Richman

Since Specialization

Citations

This map shows the geographic impact of Susan D. Richman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan D. Richman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan D. Richman more than expected).

Fields of papers citing papers by Susan D. Richman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan D. Richman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan D. Richman. The network helps show where Susan D. Richman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Susan D. Richman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Susan D. Richman Line = papers co-authored together Susan D. Richman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Multiplexed Digital PCR Reference Gene Measurement for Genomic and Cell-Free DNA Analysis Cells ·송민경,Abida Kadi,Jo Vandesompele,Alison Campbell,Susan D. Richman,Henry M. Wood,Jim F. Huggett,Carole A. Foy,Alison S. Devonshire	2025	0
2	Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy npj Precision Oncology ·Maxime W. Lafarge,Enric Domingo,Korsuk Sirinukunwattana,Somanathan,Leslie Samuel,Graeme I. Murray,Susan D. Richman,Andrew Blake,David Sebag‐Montefiore,Simon Gollins,E. Klieser,Daniel Neureiter,Florian Huemer,Richard Greil,Philip D. Dunne,Philip Quirke,Lukas Weiß,Jens Rittscher,Tim Maughan,Viktor H. Koelzer	2024	9
3	Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone British Journal of Cancer ·Sanne ten Hoorn,Dirkje W. Sommeijer,Faye Elliott,David J. Fisher,Tim R. de Back,Anne Trinh,Lianne Koens,Tim Maughan,Jenny F. Seligmann,Michel Seymour,Philip Quirke,Richard Adams,Susan D. Richman,Cornelis J.A. Punt,Louis Vermeulen	2021	11
4	Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA Epigenomes ·Celina Whalley,Karl Payne,Enric Domingo,Andrew Blake,Susan D. Richman,Jill Brooks,Nikolaos Batis,Rachel Spruce,Hisham Mehanna,Paul Nankivell,Andrew D. Beggs	2021	9
5	Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNA Scientific Reports ·Thomas L. Dunwell,松井ふみ子,Noel Peters,Nicole Pereira de Lima,Philipp Becker,Sarah Scaife,Susan D. Richman,Henry M. Wood,Floor van Lieshout,L Costamagna,Xiangsheng Yang,Hui Xiao,Sissel Gyrid Freim Wahl,Bjørn Henning Grønberg,Anita Šerkezi,Guoliang Fu	2021	4
6	A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment Molecular Oncology ·川口透,Stephanie G. Craig,Victoria Bingham,Гончар Анна,Matthew P. Humphries,Suzana Andreoli Marques Ezquina,Susan D. Richman,Philip Quirke,Leticia Campo,Enric Domingo,Tim Maughan,Jacqueline A. James,Manuel Salto‐Tellez	2020	69
7	Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel Annals of Oncology ·Jenny F. Seligmann,Faye Elliott,Susan D. Richman,Gemma Hemmings,Sarah Brown,Bart Jacobs,Christopher J.M. Williams,Sabine Tejpar,Jennifer H. Barrett,Philip Quirke,Michel Seymour	2020	12
8	Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies The Journal of Pathology ·Jennifer Holmes,Susan D. Richman,Simon Gollins,Peter Stewart,Chris Hurt,Richard Adams,Amy M.B. McCorry,J.M.T. van der Westhuizen,Dale Vimalachandran,Claudio Isella,Enzo Médico,Tim Maughan,Darragh G. McArt,Mark Lawler,Philip D. Dunne	2018	40
9	Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification Nature Communications ·Philip D. Dunne,Jennifer Holmes,Paul G. O’Reilly,J.M.T. van der Westhuizen,Amy M.B. McCorry,Susan D. Richman,Tim Maughan,Simon S. McDade,Patrick G. Johnston,Daniel B. Longley,Elaine W. Kay,Darragh G. McArt,Mark Lawler	2017	53
10	FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, BRAF and PIK3CA White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·Susan D. Richman,Richard Adams,Ewan Brown,Lynne Brown,Rachel Butler,Clifford Manyo Ntui,David I. Fisher,Raphael Kaplan,Gary Middleton,Philip Quirke,Leslie Samuel,Jenny F. Seligmann,Seymour,Islem Mhiri,Harpreet Wasan,Richard H. Wilson,Tim Maughan	2017	1
11	Epidermal growth factor receptor (EGFR) copy number (CN) as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC) Annals of Oncology ·Jenny F. Seligmann,Henry M. Wood,Susan D. Richman,Faye Elliott,Morag Taylor,Emma Tinkler‐Hundal,Jennifer H. Barrett,Michel Seymour,Philip Quirke	2017	2
12	FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS Annals of Oncology ·Richard Adams,Ewan Brown,Louise Brown,Rachel Butler,康史宮本,David J. Fisher,Raphael Kaplan,Philip Quirke,Susan D. Richman,Leslie Samuel,Jenny F. Seligmann,Michel Seymour,Kai‐Keen Shiu,Harpreet Wasan,Richard H. Wilson,Tim Maughan	2016	3
13	Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials Annals of Oncology ·Jenny F. Seligmann,David J. Fisher,Christopher G. Smith,Susan D. Richman,Faye Elliott,Sarah Brown,Richard Adams,Tim Maughan,Philip Quirke,Jeremy P. Cheadle,Michel Seymour,Gary Middleton	2016	124
14	Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival Clinical Cancer Research ·Christopher G. Smith,David J. Fisher,Rebecca Harris,Tim Maughan,Amanda I. Phipps,Susan D. Richman,Michel Seymour,Ian Tomlinson,Dan Rosmarin,David Kerr,Andrew T. Chan,Ulrike Peters,Polly A. Newcomb,Shelley Idziaszczyk,Hannah D. West,Angela Meade,Richard Kaplan,Jeremy P. Cheadle	2015	16
15	Deficient mismatch repair: Read all about it (Review) International Journal of Oncology ·Susan D. Richman	2015	127
16	Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studiesbreakdown → Clinical Cancer Research ·Sabine Venderbosch,Irıs D. Nagtegaal,Tim Maughan,Christopher G. Smith,Jeremy P. Cheadle,David J. Fisher,Richard Kaplan,Philip Quirke,Michel Seymour,Susan D. Richman,Gerrit A. Meijer,Bauke Ylstra,Daniëlle A.M. Heideman,Anton F. J. de Haan,Cornelis J.A. Punt,Miriam Koopman	2014	534
17	A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO) European Journal of Cancer ·Gary Middleton,Sarah Brown,Catherine Lowe,Tim Maughan,Stephen J. Gwyther,Alfred Oliver,Susan D. Richman,Marina Silva Tomé,Vicky Napp,Helen Marshall,Jonathan Wadsley,Nick Maisey,Ian Chau,Mark Hill,Simon Gollins,Sun Myint,Sarah Slater,John Wagstaff,John Bridgewater,Michel Seymour	2013	19
18	Value of Mismatch Repair, KRAS , and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancerbreakdown → Journal of Clinical Oncology ·Gordon Hutchins,Katie Southward,Kelly Handley,Laura Magill,Claire Beaumont,Jens Stahlschmidt,Susan D. Richman,Philip Chambers,Michel Seymour,David Kerr,Richard Gray,Philip Quirke	2011	505
19	MLH1 −93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer International Journal of Cancer ·James M. Allan,Ömer Akbudak,Julian Adlard,Jonathan Bury,Tueros Salazar,M Zhao,Mark Katory,Philip Quirke,Susan D. Richman,Daniel Scott,Kathryn Scott,Michel Seymour,Lois B. Travis,Lisa Worrillow,D. Timothy Bishop,Angela Cox	2008	41
20	Prediction of the response of colorectal cancer to systemic therapy The Lancet Oncology ·Julian Adlard,Susan D. Richman,Michel Seymour,Philip Quirke	2002	79

About Susan D. Richman

Susan D. Richman is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine, having authored 76 papers that have together received 3.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (59 papers), Genetic factors in colorectal cancer (26 papers), Cancer Genomics and Diagnostics (24 papers), Lung Cancer Treatments and Mutations (18 papers), Cancer Treatment and Pharmacology (10 papers), Gastric Cancer Management and Outcomes (10 papers), Colorectal Cancer Screening and Detection (9 papers) and Colorectal and Anal Carcinomas (9 papers). The work is most often cited by research in Oncology (2.6k citations), Pathology and Forensic Medicine (1.6k citations) and Cancer Research (711 citations). Susan D. Richman has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Philip Quirke, Michel Seymour, Philip Chambers, Catherine Daly, Faye Elliott, Jennifer H. Barrett, Angela Meade, Tim Maughan, Gordon Hutchins and David Kerr. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Clinical Pathology, European Journal of Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact